PHARMACYTE BIOTECH INC (PMCB)       2.75  -0.08 (-2.83%)

PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital

PharmaCyte Biotech Rebukes Iroquois’ Commencement of Consent Solicitation

PharmaCyte Biotech Commences First Phase of Two-Phase Pig Study

PharmaCyte Biotech Reports Positive Interim Results in Malignant Ascites Mouse Model Study

PharmaCyte Biotech Announces Preliminary Unaudited Financial Results for Fiscal Year 2022

IROQUOIS CAPITAL COMMENCES CONSENT SOLICITATION TO RECONSTITUTE PHARMACYTE BIOTECH BOARD OF DIRECTORS

/PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), announced that on Friday, July 8, 2022, that it had delivered a...

IROQUOIS CAPITAL ISSUES STATEMENT IN RESPONSE TO RECENT ACTIONS BY THE PHARMACYTE BIOTECH BOARD OF DIRECTORS

/PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc....

PharmaCyte Biotech Announces Additional Quality Control Assay and Confirms Stability of CypCap Cells

IROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING

/PRNewswire/ -- Iroquois Capital Management, LLC (together with its affiliates, "Iroquois"), one of the largest stockholders of PharmaCyte Biotech, Inc....

PharmaCyte Biotech Issues Follow-Up Response to Iroquois Capital’s Second Letter on June 9 and Reiterates Commitment to Increasing Shareholder Value

PharmaCyte Biotech to Attend 2022 BIO International Convention in San Diego

PharmaCyte Biotech Issues Response to Iroquois Capital Letter and Announces Additional Steps to Increase Shareholder Value

PharmaCyte Biotech to Implement $10-Million Share Repurchase Program

PharmaCyte Biotech Initiates Studies to Confirm Its Pancreatic Cancer Therapy Can Treat Malignant Ascites

PharmaCyte Biotech to Attend 15th International Conference on Advanced Technologies and Treatments for Diabetes

PharmaCyte Biotech Announces More Positive Tests Results for Its Pancreatic Cancer Clinical Trial Product Candidate to Satisfy FDA Requirements

PharmaCyte Biotech to Accelerate Preparations for Start of Pancreatic Cancer Clinical Trial

PharmaCyte Biotech Appoints Dr. Matthias Löhr to Board of Directors

PharmaCyte Biotech Successfully Completes 24-Month Stability Study of Its Clinical Trial Product Candidate

PharmaCyte Biotech Reports Third Quarter Financial Results and Operational Highlights

PharmaCyte Biotech Announces Genetic Stability of Cytochrome P450 Gene and Site of Integration

PharmaCyte Biotech Updates Status of Investigational New Drug Application to FDA

PharmaCyte Biotech to Present at H.C. Wainwright BioConnect Conference

PharmaCyte Biotech Study Proves Capsule Material Is Not Toxic For Encapsulated Cells

PharmaCyte Biotech Successfully Completes 36 Month Master Cell Bank Stability Study

PharmaCyte Biotech Reports Second Quarter 2021 Financial Results and Operational Highlights

PharmaCyte Biotech Successfully Completes Cytochrome P450 Site of Integration DNA Sequencing Assay

PharmaCyte Biotech Launches Malignant Ascites Program with Commencement of Pivotal Preclinical Study